How much funding has Stromedix raised?

Stromedix has raised $25.0M in total funding, most recently a Series C round.

Who are Stromedix's investors?

Stromedix's investors include New Leaf Venture Partners, Atlas Venture, Red Abbey Venture Partners.

Where is Stromedix headquartered?

Stromedix is headquartered in Cambridge, Massachusetts, United States.

What industry is Stromedix in?

Stromedix operates in Biotech, Therapeutics.

Stromedix

Acquired

Cambridge, United States · Founded 2006 · $25.0M raised

Biotech

Therapeutics

Headquarters: Cambridge, Massachusetts
Employees: 1–10
Founded: 2006
Business Model: B2B

Website: stromedix.com
Total Funding: $25.0M
Last Round: $25.0M Series CJan 2011
Rounds: 3

About

Stromedix, Inc. was a privately held biotechnology company founded in 2006 by Michael Gilman in Cambridge, Massachusetts, focused on developing innovative therapies for fibrosis and organ failure. The company's lead program was STX-100, an integrin αvβ6 inhibitor originally licensed from Biogen Idec, targeting idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. Stromedix raised $25 million in venture funding and advanced STX-100 into clinical development before being acquired by Biogen Idec in March 2012 for $75 million upfront plus up to $487.5 million in milestone payments, valuing the deal at up to $562.5 million. The acquisition brought Stromedix's fibrosis pipeline into Biogen's research organization, where Gilman subsequently served as Executive Vice President of Research.

Summary

Stromedix is a Biotech company based in Cambridge, United States, founded in 2006. It has raised $25.0M in total across 3 rounds, most recently a $25.0M Series C round in Jan 2011. Investors include New Leaf Venture Partners, Atlas Venture and Red Abbey Venture Partners.